APLN and chronic kidney disease: To reveal the therapeutic potential of apelin for skeletal muscle atrophy under the CKD condition, we administered apelin (1.0 μmol/kg) 8 weeks after the 5/6‐Nx, which was considered to be a turning point for apelin expression alteration in the skeletal muscle (Figure 5).